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The pathologist – a key person in a multidisciplinary 
team of breast cancer
Summary
Diagnosis and treatment of breast cancer has progressed rapidly in recent 
20 years. The diagnosis was first based on clinical appearance that changes 
after the introduction of mammography in the diagnosis. Development of 
radiological techniques has led to the detection of a small and non-palpable 
lesions, and surgeons are increasingly applied conserving procedures for breast 
cancer. Therefore, today is a very important multidisciplinary team in the 
treatment of patients with breast cancer. A pathologist is a key member of 
the multidisciplinary team because must determine the number of prognos-
tic and predictive factors for patients with breast cancer which requires some 
standardized protocols and processing of tissue samples.
 
IntroductIon
Breast cancer is the most common cancer among women in both developing and developed regions in the world. Clinical cancer de-
velops over a long period of time, requires multiple molecular alterations, 
and involves evolution of cellular populations with increasingly aggres-
sive phenotypic characteristics (1). Although the time required for the 
process of carcinogenesis is not well established for any human cancer, 
estimate suggest that this multistep process unfolds over many years and 
possibly several decades. Breast cancer represents a diverse collection of 
malignant diseases of the breast with highly variable clinical behaviors 
and disparate response to therapy (2).
Personalized oncology is evidence-based, individualized medicine 
that delivers the right care to the right cancer patient at the right time 
and results in measurable improvements in outcomes and a reduction 
on health care costs. The essence of personalized oncology lies in the use 
of biomarkers. The biomarkers can be from tissue, serum,urin or imag-
ing and must be validated. Also, their have different importances: pre-
dictive, prognostic and early response biomarkers.
The diagnosis and treatment of breast cancer has rapidly evolved over 
the past 20 years. In the first part of the 20th century, treatment of breast 
cancer consisted of radical mastectomy, but adjuvant systemic treatment 
and adjuvant radiotherapy did not play a major role. Diagnosis of breast 
cancer was mostly made based on clinical presentation, later aided by 
mammography and often combined with frozen section pathology con-
firmation. Starting in the 1980s, there have been important alterations 
in the diagnosis and treatment of breast cancer, having an important 
impact on the diagnostic procedure employed by pathologists.
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Histopathological prognostic and 
predictive factors
Histopathological features play an important role in 
guiding the treatment decisions. In addition, genetic re-
search is starting to have an increasing impact on guiding 
therapy by providing prognostic and predictive factors (3).
To obtain optimal morphology in the histology sec-
tions, and to obtain optimal immunohistochemical stain-
ing results, the resection specimen should be cut into thin 
slices immediately after surgery.
For microscopic examination the pathologist should 
be obtained and processed for paraffin sections full diam-
eter of the tumour and its surroundings, small part of the 
tumour to perform immunohistochemistry, if there are 
macroscopical or radiological abnormalities in the tissue 
surrounding the invasive tumour, these areas should be 
sampled. If the surrounding tissue is without abnormali-
ties, it is necessary to take at least two sections from mac-
roscopically normal breast tissue.
On slides stained with hematoxylin eosin (H.E.), pa-
thologist must determine the prognostic and predictive 
factors for breast cancer. This includes the histological 
type of cancer (4), the degree of tumour differentiation 
and nuclear grade (5), mitotic counts, peritumoral lym-
phovascular invasion, estrogen and progesterone receptors 
(6), protein HER-2 (7) and proliferative index Ki–67 (8).
Molecular markers as prognostic 
factors
Receptors are determined by immunohistochemistry 
and the results are expressed as the percentage of positive 
cells and intensity of staining. Staining for estrogen and 
progesterone receptor is allways nuclear in localization 
and in most institutes all patients with a tumour in which 
more than 10% or more 1% of the tumour cells show 
positive staining regardless of the intensity of staining are 
candidates for adjuvant hormonal therapy. According to 
the consensus of the St Gallen 2013. cut-off of the pro-
gesterone receptors is 20%. This value best separating 
luminal type A from luminal type B breast cancer. Values 
below 20% indicate that the progesterone receptors are 
negative or low (9). When negative staining for estrogen 
and/or progesterone receptor is seen, it is important to 
confirm that staining of the hormone receptor-negative 
case has been successful. This can usually be tested, since 
the majority of normal breast tissues contain some nuclei 
ducts and lobules that are positive for estrogen and pro-
gesterone receptor. If no normal breast epithelial cells are 
found to show positive staining, the hormone receptor 
assays should be repeated on another tumour block.
HER-2 gene amplification is observed in 15–30% of 
invasive breast cancers and leads to HER-2 receptor over-
expression. HER-2 positive invasive breast cancers re-
spond favourable to therapies that specifically target the 
HER-2 protein, therefore it is very important today to 
identify candidates for this type of targeted therapy. Sev-
eral technologies are available for determining HER-2 
status, but the two most commonly used are immunohis-
tochemistry (IHC), which measures HER-2 protein ex-
pression and CISH (chromogen in situ hybridisation) 
which detects HER-2 gene amplification a method that 
is often used today in the pathology than FISH (fluores-
cence in situ hybridisation). The interpretation of the re-
sults is based on the intensity and percentage of stained 
cells. The most commonly used score system is 0, 1+ 
(negative results), 2+ and 3+ (positive results). A 2+ is 
considered equivocal and should be followed by retesting 
by CISH. Women with IHC 3+ tumours are candidates 
for therapy with trastuzumab, but women with 2+ tu-
mour should be retested and if the results show amplifica-
tion of gene of those are candidates for trastuzumab. To 
ensure the highest possible accuracy, pathology centers 
must standardise methodologies and testing procedures.
Proliferative index is also very important and is deter-
mined by immunohistochemistry by monoclonal anti-
body Ki-67. Positive reaction is nuclear reaction and are 
counted positive nuclei in 1000 tumour cells on the high 
magnification and the results obtained is expressed as a 
percentage of positive nuclei. According to St Gallen con-
sensus cut of value is 20% of positive cells, which means 
that below this value is low and value above 20% is high 
proliferative index (9).
Based on the receptors, HER-2 status and proliferative 
index breast cancers are classified immunophenotypi-
cally into five subgroups: luminal type A, luminal type B 
HER-2 negative, luminal type B Her-2 positive, HER-2 
positive (non-luminal type) and triple negative tumours. 
Based on the immunophenotype of the cancer patients 
receive appropriate therapy. The multi-gene testing re-
mains inaccesible for the majority of women with early 
breast cancer, therefore is adopted clinico-pathological 
testing, now expressed in surrogate IHC-based classifica-
tion.
In the widest sense, post-therapy effects include mor-
phololgical and biological alterations in cancer and nor-
mal tissue after any treatment. The patients have no or 
little response, and the majority has a partial response to 
therapy. The extent of this response is associated with 
outcome. Identifying stage after treatment is important 
and provides additional prognostic information. The re-
sponse in lymph nodes has more prognostic importance 
than does response in the breast. Small metastases after 
treatment, including isolated tumour cells, are representa-
tive of an incomplete pathological response (10).
the role of tumor enviroment
However, the tumour microenviroment has been rec-
ognized to play an important role in oncogene-addicted 
tumours as well as the success of therapeutic responses to 
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targeted agents. In cancer therapeutics, the immune sys-
tem has been shown to be important through its contribu-
tion to the efficacy of cancer therapeutics. The role of the 
immune system in HER-2 positive breast cancers is large-
ly undefined, as breast cancers have long been thought 
not to be amenable to immune approaches. However, 
lymphocytic infiltration, in most cases representing a T-
cell infiltrate, is correlated with better clinical outcomes 
in an increasing number of large breast cancer datasets. 
The quantity of lymphocytic infiltration assessed in tu-
mours at baseline has also been associated with increased 
sensitivity to chemotherapy (higher pathological complete 
response rates) (11). Similarly, breast cancer that are of the 
triple-negative subtype also have a much better outcome 
if they have high levels of lymphocytic infiltration at di-
agnosis and if they receive anthracycline-based adjuvant 
chemotherapy (12). If patients have HER-2 positive breast 
cancer and infiltration of lymphocytes in a tumour, the 
finding of tumor infiltrating lymphocytes (TILs) can not 
be recommended as a guide who should or should not 
receive trastuzumab, but they may ultimately help define 
a good prognostic group of patients that may not require 
further addition to trastuzumab or may predict increased 
benefit from T-cell checkpoint inhibitors and other im-
munotherapies (11). The simplest method of determining 
lymphocytic infiltration is on haematoxylin and eosin 
slides. It is still a semiquantitative method based on a 
pathologists subjective assesment (13).
We investigated the expression of MAGE family gene 
in invasive ductal breast cancers. Their products encom-
pass tumour associated antigenes (TAAs) recognised by 
human leucocyte antigen (HLA)- restricted specific T-
cells.These genes, especially their products are of particu-
lar interest in tumor immunology (14). By using a mono-
clonal antibody specific for MAGE family gene products, 
we have studied the expression of these TAAs in group of 
144 patients with invasive ductal breast cancers. Immu-
nohistochemical data were correlated with pathohisto-
logical prognostic factors, and the expression of MAGE 
gene products was typically detectable in poorly differen-
tiated invasive ductal breast cancer. The data also support 
the concept of specific immunotherapy procedures target-
ing MAGE family TAA in highly aggressive forms of 
breast cancerv (15).
concLuSIon
Numerous studies in recent years have identified many 
prognostic and predictive factors for breast cancer. Most 
of them determined pathohistologically, which resulted 
in a large responsibility for pathologists. In addition, pa-
thologist has become a key person in a multidisciplinary 
team of breast cancer and the person very responsible for 
the implementation of specific individual therapy.
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